



EFW

PATENT
Attorney Docket 036870-5045-14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Michael Zasloff *et al.*)
Application No. 10/824,661) Group Art Unit: 1616
Filed: April 15, 2004) Examiner: Not Assigned
For: Aminosterol Compounds Useful as Inhibitors)
of the Sodium/Proton Exchanger (NHE),)
Pharmaceutical Methods and Compositions)
Employing Such Inhibitors, and Processes)
for Evaluating the NHE-Inhibitory)
Efficacy of Compounds)

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Official Filing Receipt received from the U.S. Patent Office in the above-referenced application for which issuance of a corrected filing receipt is respectfully requested as there are errors with respect to the assignment and the power of attorney data.

The present application is a continuation application of Application No. 09/985,417, filed November 2, 2001, now U.S. Patent No. 6,962,909, which is a continuation application of Application No. 09/198,486, filed November 24, 1998, which is a continuation application of Application No. 08/487,443, filed June 7, 1995, now U.S. Patent No. 5,847,172.

1. Assignment Data: Attached is a copy of the Patent Assignment Abstract of Title for parent Application No. 08/487,443 reflecting the Change of Name recorded on August 15, 2001. Please correct the Assignment Data to read: Genaera Corporation.

2. Power of Attorney Data: Attached is a copy of the Acceptance of Power of Attorney received in parent Application No. 08/487,443. Please correct the Power of Attorney Data to read: The patent practitioners associated with Customer Number 09629.

If there are any fees due in connection with the filing of this Request, please charge the fees to our Deposit Account No. 50-310. If a fee is required for an extension of time under 37

Attorney Docket 036870-5045-14

Application No. 10/824,661

Page 2

C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **May 5, 2006**

Morgan, Lewis & Bockius LLP


Customer No. **09629**

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

202-739-3000


Respectfully submitted,
Morgan, Lewis & Bockius LLP



Gregory T. Lowen
Registration No. 46,882



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/824,661	04/15/2004	1616	667	036870-5045-14	19	21	3

009629
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004

CONFIRMATION NO. 7684
UPDATED FILING RECEIPT



OC000000018543782

Date Mailed: 04/14/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael Zasloff, Merion Station, PA;
Ann Shinnar, Teaneck, NJ;
William Kinney, Churchville, PA;
Steven Jones, West Chester, PA;

Assignment For Published Patent Application

Magainin Pharmaceuticals Inc.

Genaera Corporation

Power of Attorney:

The patent practitioners associated with Customer Number 09629

Donald Dunner-19073
Douglas Henderson-20291
Arthur Garrett-20338
Clair Mullen Jr-20348
Richard Smith-20609

Ford Farabow Jr-20630
Tipton Jennings-20645
Laurence Hefter-20827
Brian Brunsvold-22593
Albert Santorelli-22610

Domestic Priority data as claimed by applicant

This application is a CON of 09/985,417 11/02/2001 PAT 6,962,909
which is a CON of 09/198,486 11/24/1998 ABN
which is a CON of 08/487,443 06/07/1995 PAT 5,847,172

Foreign Applications

RECEIVED

APR 17 2006

If Required, Foreign Filing License Granted: 06/26/2004

MORGAN, LEWIS & BOCKIUS LLP

The country code and number of your priority application, to be used for filing abroad under the Paris

Convention, is US10/824,661

Projected Publication Date: 07/27/2006

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds

Preliminary Class

552

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184**

Title 37, Code of Federal Regulations, 5.11 & 5.15**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)



Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 3

Patent #: 5847172 **Issue Dt:** 12/08/1998 **Application #:** 08487443 **Filing Dt:** 06/07/1995

Inventors: MICHAEL ZASLOFF, ANN SHINNAR, WILLIAM KINNEY, STEVEN JONES

Title: CERTAIN AMINOSTEROL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE COMPOUNDS

Assignment: 1

Reel/Frame: 007628/0865 **Recorded:** 08/25/1995 **Pages:** 4

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: <u>ZASLOFF, MICHAEL</u>	Exec Dt: 08/21/1995
<u>SHINNAR, ANN</u>	Exec Dt: 08/16/1995
<u>KINNEY, WILLIAM</u>	Exec Dt: 08/18/1995
<u>JONES, STEVEN</u>	Exec Dt: 08/18/1995

Assignee: MAGAININ PHARMACEUTICALS INC.
5110 CAMPUS DRIVE
PLYMOUTH MEETING, PENNSYLVANIA 19462

Correspondent: FINNEGAN, HENDERSON, FARABOW ET AL

LINDA S. EVANS
1300 I STREET, N.W., SUITE 700
WASHINGTON, D.C. 20005-3315

Assignment: 2

Reel/Frame: 008389/0001 **Recorded:** 02/27/1997 **Pages:** 18

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: MAGAININ PHARMACEUTICALS INC., A CORPORATION OF PENNSYLVANIA **Exec Dt:** 09/17/1996

Assignee: MAGAININ PHARMACEUTICALS INC., A CORPORATION OF DELAWARE
5110 CAMPUS DRIVE
PLYMOUTH MEETING, PENNSYLVANIA 19462

Correspondent: FINNEGAN, HENDERSON, FARABOW ET AL

WILLIAM R. RAUCHHOLZ
1300 I STREET, N.W.
WASHINGTON, D.C. 20005

Assignment: 3

Reel/Frame: 012061/0506 **Recorded:** 08/15/2001 **Pages:** 10

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: MAGAININ PHARMACEUTICALS, INC. **Exec Dt:** 03/09/2001

Assignee: GENAERA CORPORATION



3110 CAMPUS DRIVE
PLYMOUTH MEETING, PENNSYLVANIA 19462

Correspondent: MORGAN, LEWIS & BOCKIUS LLP

MR. REID G. ADLER
1800 M STREET NW
WASHINGTON, D.C. 20036

Search Results as of: 05/03/2006 03:45 PM

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350

| [HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



UNITED STATES DEPARTMENT OF COMMERCE
PATENT and TRADEMARK OFFICE
ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

36870-

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET
08/487443	06/07/95	ZASLOFF	5387.0045-

FINNEGAN HENDERSON FARABOW
GARRETT AND DUNNER
1300 I STREET NW
WASHINGTON DC 20005-3315

RECEIVED

EXAMINER
PRIOR, KIMBERL

JUN 14 1999
MORGAN, LEWIS & BOCKIUS LLP DATE MAILED: 06/
ART UNIT 1 PAPER NO 1616

This is a communication from
the Patent & Trademark Office

PATENT NUMBER: 5.

This is in response to the Power of Attorney filed 12/21/98

() 1. The Power of Attorney to you in this application has been revoked by the applicant. Future correspondence will be mailed to the new address of record. 37 CFR 1.33.

() 2. The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record. (37 CFR 3.71)

() 3. The withdrawal as attorney in this application has been accepted. Future correspondence will be mailed to the new address of record. 37 CFR 1.33.

(✓) 4. The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the below-noted address as provided by 37 CFR 1.33.

() 5. The Power of Attorney in this application is not accepted for the reason(s) checked below:

() a. The Power of Attorney is from an assignee and the Certificate required by 37 CFR 3.73(b) has not been filed.

() b. The person signing for the assignee has omitted their empowerment to sign on behalf of the assignee. 37 CFR 3.71

() c. The inventor(s) is without authority to appoint attorneys since the assignee has intervened as provided by 37 CFR 3.71.

() d. The signature of _____, a co-inventor, has been omitted. The Power of Attorney will be entered upon receipt of confirmation by said co-inventor.

() e. The person(s) appointed in the Power of Attorney is not registered to practice before the U.S. Patent and Trademark Office.

() f. The revocation is not signed by the applicant, the assignee of the entire interest, or one particular attorney having the authority to revoke.

009629

MORGAN, LEWIS & BOCKIUS
1800 M STREET NW
WASHINGTON DC 20036-5869

For questions call

DOC

By